Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients
- 18 May 2004
- journal article
- clinical trial
- Published by Elsevier BV in Blood Cells, Molecules, and Diseases
- Vol. 33 (1), 57-63
- https://doi.org/10.1016/j.bcmd.2004.04.004
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Towards the pharmacogenomics of cystic fibrosisPharmacogenomics, 2002
- Heterodimer-Loaded Erythrocytes as Bioreactors for Slow Delivery of the Antiviral Drug Azidothymidine and the Antimycobacterial Drug EthambutolAIDS Research and Human Retroviruses, 1999
- Cystic fibrosis.American Journal of Respiratory and Critical Care Medicine, 1996
- Dexamethasone for the prevention of postextubation airway obstructionCritical Care Medicine, 1996
- A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosisThe Journal of Pediatrics, 1995
- Red blood cells as a delivery system for AZTDrug Delivery, 1995
- Corticosteroid treatment in cystic fibrosis.Archives of Disease in Childhood, 1993
- Conversion of encapsulated 5-fluoro-2'-deoxyuridine 5'-monophosphate to the antineoplastic drug 5-fluoro-2'-deoxyuridine in human erythrocytes.Proceedings of the National Academy of Sciences of the United States of America, 1988
- Improved Oxygen Delivery to Tissues and Iron Chelator Transport through the Use of Lysed and Resealed Red Blood Cells: A New Perspective on Cooley's Anemia TherapyaAnnals of the New York Academy of Sciences, 1985
- Enzyme Loading of ErythrocytesProceedings of the National Academy of Sciences, 1973